Latham Advises Impilo on Sale of Immedica Pharma to KKR

Latham & Watkins has advised Impilo on the sale of its portfolio company, Immedica Pharma, a European pharmaceutical company headquartered in Stockholm, Sweden, focused on the commercialization of medicines for rare diseases and specialty care products, to investment funds managed by KKR.

As part of the strategic partnership, Impilo will reinvest to become an equal owner in Immedica Pharma alongside KKR after closing. The transaction is subject to customary regulatory and closing conditions.

The Latham team was led by London corporate partner Robbie McLaren, with associates Samantha Peacock, Antonina Semyachkova, and Alexander Fedorkov. Advice was also provided on Life Sciences matters by Paris partner Eveline Van Keymeulen, with London associate Oliver Mobasser and Paris associate Jeanne Fabre; on DTT matters by London partner Gail Crawford and London associate Kate Burrell; on tax matters by London partner Sean Finn and associate Thomas O’Malley; on antitrust matters by Brussels partner Héctor Armengod and associates Giuseppe Liotine and Romain Perrois; on litigation matters by London associate Olivia Featherstone; on sanctions matters by London partner Robert Price and associate Michelle Taylor; and on anti-bribery and corruption matters by London partner Nathan Seltzer and associates Mair Williams and Matthew Unsworth.